[ad_1]
French pharmaceutical giant Sanofi said international phase 3 clinical trials of its Kevzara drug for severe cases of Covid-19 had been inconclusive and it was halting the trial.
The Phase 3 trial, usually the last one before official approval for use, “did not meet the primary or secondary endpoints compared to placebo, and in both cases compared to established hospital care,” he said. it’s a statement.
Sanofi said that neither he nor his US drug development partner Regeneron “foresee further clinical trials of Kevzara for the treatment of Covid-19.”
Although Kevzara “did not give us the results we expected, we are proud of the work our team has done,” Sanofi’s head of global research John Reed said in the statement.
Since the outbreak of the coronavirus pandemic late last year in China, it has claimed more than 800,000 lives and caused enormous economic damage, sparking a global race to find an effective vaccine and treatments.
Latest coronavirus stories
Sanofi is one of many companies developing a vaccine, but scientists are cautious in saying that at best, only one may be available by the end of this year for initial use.
AstraZeneca and Oxford Biomedica Expand Covid-19 Vaccine Supply
AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker’s Covid-19 candidate vaccine as it seeks to increase supply ahead of possible fast-track approval from the US.
Cell and gene therapy firm Oxford Biomedica said AstraZeneca would give it $ 15 million upfront to reserve manufacturing capacity at its plant and that it could get an additional $ 35 million plus other costs through the end of 2021 under the new 18-month deal. .
AstraZeneca’s hopeful vaccine for the novel coronavirus, AZD1222, which is already among the top candidates in the global race for a successful vaccine, moved to advanced-stage trials in the US this week as the company targets 3 billion doses of the vaccine.
Oxford Biomedica was one of AstraZeneca’s initial partners when they came together in May to produce the vaccine, and today’s deal could be extended further in another year and a half in 2022 and 2023, Oxford said.
[ad_2]